BeiGene (NASDAQ:BGNE) had its target price upped by stock analysts at Maxim Group from $200.00 to $225.00 in a report issued on Friday. The firm currently has a “buy” rating on the stock. Maxim Group’s target price would suggest a potential upside of 18.98% from the stock’s current price.
Other analysts have also recently issued research reports about the company. Zacks Investment Research raised BeiGene from a “hold” rating to a “buy” rating and set a $190.00 target price for the company in a research report on Tuesday, May 1st. BidaskClub raised BeiGene from a “hold” rating to a “buy” rating in a research report on Wednesday, January 31st. Ladenburg Thalmann reaffirmed a “buy” rating and issued a $172.00 target price on shares of BeiGene in a research report on Thursday, March 1st. They noted that the move was a valuation call. ValuEngine raised BeiGene from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Robert W. Baird reaffirmed a “hold” rating and issued a $138.00 target price on shares of BeiGene in a research report on Thursday, March 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $173.00.
Shares of NASDAQ BGNE opened at $189.11 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 11.12 and a current ratio of 11.18. The firm has a market capitalization of $9.81 billion, a P/E ratio of -84.80 and a beta of 0.29. BeiGene has a 52-week low of $184.00 and a 52-week high of $187.13.
In other BeiGene news, CEO John Oyler sold 99,000 shares of the business’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $145.63, for a total value of $14,417,370.00. Following the completion of the sale, the chief executive officer now owns 93,883 shares of the company’s stock, valued at $13,672,181.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Ji Li sold 10,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $146.88, for a total value of $1,468,800.00. Following the completion of the sale, the executive vice president now directly owns 10,000 shares of the company’s stock, valued at approximately $1,468,800. The disclosure for this sale can be found here. In the last ninety days, insiders sold 194,210 shares of company stock valued at $29,041,676. 19.90% of the stock is currently owned by insiders.
Large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC acquired a new stake in shares of BeiGene in the fourth quarter worth about $182,000. Comerica Bank acquired a new stake in shares of BeiGene in the fourth quarter worth about $246,000. Mackenzie Financial Corp acquired a new stake in shares of BeiGene in the fourth quarter worth about $250,000. Jefferies Group LLC acquired a new stake in shares of BeiGene in the fourth quarter worth about $283,000. Finally, Quantbot Technologies LP acquired a new stake in shares of BeiGene in the first quarter worth about $290,000. 51.88% of the stock is owned by institutional investors.
BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.